Robert W. Ross - Mar 1, 2023 Form 4 Insider Report for Surface Oncology, Inc. (SURF)

Role
Chief Executive Officer
Signature
/s/ Jessica Fees, as Attorney-in-Fact
Stock symbol
SURF
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/3/2023, 07:00 PM
Previous filing
Aug 5, 2022
Next filing
Jun 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SURF Stock Option (Right to Buy) Award $0 +400K $0.00 400K Mar 1, 2023 Common Stock 400K $0.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Options shall vest in full on February 8, 2024, so long as the reporting person remains an employee or other service provider of the Issuer on such date.